Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Urapidil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Hasten
Deal Size : $322.0 million
Deal Type : Divestment
Details : The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China which includes Ebrantil®.
Brand Name : Ebrantil
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 21, 2020
Lead Product(s) : Urapidil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Hasten
Deal Size : $322.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?